Precision medicine will enable transformative treatments for the many diseases whose diagnoses conflate multiple distinct biologies. At Owkin, we are using federated infrastructure to access multimodal data from our growing network of European and American hospitals, and applying AI to enable precision approaches to oncology and other diseases. Utilizing these resources, we are building biomarkers for patient selection, helping pharma accelerate clinical development, and discovering drug targets based on novel disease subtypes. We are excited to collaborate with academic and industrial partners towards these goals.